Quotes 5-day view Delayed Nasdaq
09/21/2020
09/22/2020
09/23/2020
09/24/2020
09/25/2020
Date
69.26(c)
68.72(c)
67.16(c)
65.17(c)
69.47(c)
Last
8 223 034
6 303 612
6 919 352
5 565 191
9 150 781
Volume
-0.87% -0.78% -2.27% -2.96% +6.60% Change
Sales 2020
305 M - -
Net income 2020
-537 M - -
Net cash position 2020
2 553 M - -
P/E ratio 2020
-48,8x
Yield 2020
-
Sales 2021
4 870 M - -
Net income 2021
864 M - -
Net cash position 2021
3 655 M - -
P/E ratio 2021
31,7x
Yield 2021
-
Capitalization
27 412 M 27 412 M -
EV / Sales 2020
81,5x
EV / Sales 2021
4,88x
Nbr of Employees
975
Free-Float
80,1%
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for infectious, autoimmune and cardiovascular diseases. Turnover per type of income can be broken down as follows:
- Collaboration revenue (79.8%);
- Grant revenue (20.2%).
At the end of 2019, the group possessed a portfolio of 6 development candidates in clinical studies, with three in phase II and...
Notations Surperformance© of Moderna, Inc.
Trading Rating : Investor Rating :
All news about MODERNA, INC.
News in other languages on MODERNA, INC.
Analyst Recommendations on MODERNA, INC.
MODERNA, INC. - 07/13
Buying pressure
BUY
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends MODERNA, INC.
Short Term Mid-Term Long Term Trends Neutral Neutral Bullish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
OUTPERFORM
Number of Analysts
15
Average target price
91,47 $
Last Close Price
69,47 $
Spread / Highest target
92,9%
Spread / Average Target
31,7%
Spread / Lowest Target
-41,0%
Please enable JavaScript in your browser's settings to use dynamic charts.
United Kingdom
Canada
France
Deutschland
Schweiz (DE)
Report
